Cancer Genetics Inc (NASDAQ:CGIX) announced its quarterly earnings results on Thursday. The medical research company reported ($0.11) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.07. The company had revenue of $7 million for the quarter, compared to analyst estimates of $7.62 million. Cancer Genetics had a negative net margin of 74.07% and a negative return on equity of 63.26%. Cancer Genetics’s revenue for the quarter was up 14.8% on a year-over-year basis. During the same quarter last year, the business earned ($0.39) EPS.
Shares of Cancer Genetics (NASDAQ:CGIX) traded down 8.54% during trading on Friday, hitting $3.75. 211,967 shares of the company’s stock were exchanged. The stock’s 50 day moving average is $3.91 and its 200 day moving average is $2.36. The firm’s market capitalization is $71.01 million. Cancer Genetics has a 1-year low of $1.10 and a 1-year high of $5.30.
A number of equities analysts have weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $6.00 price target on shares of Cancer Genetics in a report on Monday, March 27th. Zacks Investment Research lowered shares of Cancer Genetics from a “buy” rating to a “hold” rating in a report on Wednesday, February 8th.
Cancer Genetics Company Profile
Cancer Genetics, Inc is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information.